SML1315

Ranirestat

≥97% (HPLC)

• Synonym(e): (3R)-2′-[(4-Bromo-2-fluorophenyl)methyl]-spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone., AS-3201
• Empirische Formel (Hill-System): C₁₇H₁₁BrFN₃O₄
• CAS-Nummer: 147254-64-6
• Molekulargewicht: 420.19
• MDL-Nummer: MFCD00920915
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329825780
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥97% (HPLC)
• Form: powder
• Optische Aktivität: [α]/D -5 to -10°, c = 1.0 in methanol
• Farbe: white to beige
• Löslichkeit: DMSO: 20 mg/mL, clear
• Lagertemp.: −20°C
• SMILES String: O=C(N1CC2=C(F)C=C(Br)C=C2)C3=CC=CN3[C@@]4(CC(NC4=O)=O)C1=O
• InChI: 1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1
• InChIKey: QCVNMNYRNIMDKV-QGZVFWFLSA-N

Beschreibung

Biochem./physiol. Wirkung

Ranirestat (AS-3201) is an aldose reductase (AR) inhibitor. Aldose reductase is a rate-limiting enzyme in the conversion of D-glucose to fructose via D-sorbitol. Ranirestat has been implicated in diabetic complications (cataract formation, retinopathy, neuropathy, nephropathy). Ranirestat prevents sorbitol accumulation and is thus hoped to be effective in the remedy of diabetic neuropathy.

Sicherheitshinweise

• Piktogramme: GHS07
• Signalwort: Warning
• H-Sätze: H315,H319,H335
• P-Sätze: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• Gefahreneinstufungen: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• Zielorgane: Respiratory system
• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable